Rubraca Ovarian Cancer Maintenance Approval Brings PARP Inhibitor Parity On Broad Indication
Executive Summary
US FDA approval of Rubraca's all-comers maintenance therapy for platinum-sensitive ovarian cancer continues model that Zejula and Lynparza used for a broad maintenance indication, with data broken out for germline BRCA mutation-positive patients in the clinical trials section of labeling.
You may also be interested in...
EMA Restricts Rubraca’s Use Due To Concerns Over Benefit & Safety
EU doctors are being told not to prescribe Rubraca as third-line treatment for cancers of the ovary, fallopian tubes or peritoneum with a BRCA mutation.
Clovis Withdraws Rubraca Ovarian Cancer Indication Due To Survival Imbalance
Third-line BRCA-mutated ovarian cancer indication is not a major loss for Rubraca, but Clovis also faces delay in filing to add first-line ovarian cancer therapy to product label.
Fresh EU Okay For Rubraca Boosts Clovis
Rumors that Clovis is going to be an M&A target soon are on the rise after a second thumbs-up in Europe for the firm's PARP inhibitor Rubraca, this time as maintenance therapy for platinum-sensitive ovarian cancer in all-comers.